Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.
Latest full-year results from official filings.
Not stock-market listed and no listed parent identified, so no public annual accounts were found.
Financial health not assessed; a credit-agency licence (e.g. Dun & Bradstreet) would be needed.
Credible news about incidents, disputes, legal action or restructuring in the last 24 months.
Mar 2026: Thermo Fisher Scientific completed its acquisition of Clario for about $8.9bn in cash plus deferred and earn-out payments; Clario now sits within Thermo Fisher's Laboratory Products and Biopharma Services segment.
Data breaches, cyber incidents, regulator action and assurance status.
No data breaches, cyber incidents or regulator actions involving Clario found in HSH's search of the last 24 months. NHS DSPT status not yet checked.
Recalls, safety notices, regulator action and clinical safety concerns.
No product recalls, FDA warning letters or safety notices involving Clario found in HSH's search of the last 24 months.
Contract delivery, go-lives, terminations and disputes.
May 2025: Clario completed its acquisition of WCG's eCOA (electronic clinical outcome assessment) business. No contract disputes or troubled implementations involving Clario found in HSH's search of the last 24 months.